Drugs / H101
H101
Trials 25 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05675462 | Mar 2023 → Dec 2025 | hepatocellular carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 1 | NCT05303844 | Apr 2022 → Mar 2025 | refractory malignant neoplasm | Fudan University | Unknown | No outcome recorded |
| Phase 1 | NCT05303090 | Mar 2022 → Apr 2024 | pancreatic ductal adenocarcinoma | Fudan University | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06136910 | May 2023 → May 2024 | non-small cell lung carcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT06196671 | Dec 2026 → Jan 2028 expected | malignant pancreatic neoplasm | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07381309 | Jun 2026 → Feb 2028 expected | metastasis from malignant tumor of colon | Jun Huang | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07543848 | May 2026 → Dec 2028 expected | rectum adenocarcinoma | Chongqing University Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07398664 | Mar 2026 → Jun 2028 expected | head and neck squamous cell carcinoma, virus associated tumor | West China Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07356791 | Feb → Dec 2026 expected | bladder transitional cell carcinoma | RenJi Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06919848 | May 2025 → May 2027 expected | biliary tract cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06685354 | Nov 2024 → Oct 2026 expected | hepatocellular carcinoma | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06618391 | Oct 2024 → Mar 2026 overdue | non-small cell lung carcinoma | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06253598 | Mar 2024 → Dec 2025 overdue | hepatocellular carcinoma | The First Affiliated Hospital of Bengbu Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05872841 | Jun 2023 → Dec 2024 | hepatocellular carcinoma, portal vein thrombosis | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05823987 | May 2023 → Dec 2025 | biliary tract cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05564897 | Aug 2022 → Sep 2024 | urinary bladder cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05234905 | Mar 2022 → Jun 2023 | cervical cancer, virus associated tumor | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05051696 | Sep 2021 → Mar 2024 | female reproductive system neoplasm | Liu Zi | Unknown | No outcome recorded |
| Phase 2 | NCT04771676 | Mar 2021 → Jan 2023 | refractory malignant neoplasm | Fudan University | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT03780049 | Oct 2018 → Oct 2023 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT02579564 | Oct 2016 → Jun 2018 | non-small cell lung carcinoma | Xinqiao Hospital of Chongqing | Unknown | No outcome recorded |
| Phase 3 | NCT01869088 | Jan 2013 → Jan 2018 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05124002 | Aug 2022 → Apr 2026 | intrahepatic cholangiocarcinoma | Beijing Tsinghua Chang Gung Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05113290 | Dec 2021 → Dec 2023 | hepatocellular carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03790059 | Oct 2016 → Sep 2020 | hepatocellular carcinoma | Southwest Hospital, China | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H101 | “Effect and Safety of Recombinant Human Adenovirus Type 5 (H101) in Advanced Hepatocellular Carcinoma Patients With Stable Disease After Sorafenib Treatment: A Randomized,...” NCT05113290 ↗16“Participants will receive hepatic arterial infusion of recombinant human type 5 adenovirus (H101).” NCT06685354 ↗ “intratumoral injection of oncolytic virus(recombinant human adenovirus type 5 injection, H101)” NCT05234905 ↗ “Oncorine (H101)” NCT04771676 ↗ |
| Known as | Oncorine | “Oncorine (H101) with or without radiotherapy” NCT05051696 ↗ |
| Known as | Recombinant Human Adenovirus 5 | “Recombinant Human Adenovirus 5 (H101) Combined With Transcatheter Arterial Chemoembolization (TACE) for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell...” NCT07398664 ↗ |
| Known as | Recombinant human adenovirus type 5 | “intratumoral injection of oncolytic virus(recombinant human adenovirus type 5 injection, H101)” NCT05234905 ↗8“Recombinant human adenovirus type 5 injection(H101)” NCT06136910 ↗ |
| Known as | Recombinant Human Adenovirus Type 5 Injection | “Recombinant Human Adenovirus Type 5 Injection is an oncolytic adenovirus antitumor drug.” NCT07356791 ↗ |
| Known as | Recombinant Human Adenovirus Type 5 Injection（H101）. | “Recombinant Human Adenovirus Type 5 Injection（H101）.” NCT03790059 ↗ |
| Known as | Recombinant Human Type-5 Adenovirus | “Recombinant Human Type-5 Adenovirus” NCT03780049 ↗ |
| Action | Deplete | “selectively replicates in and lyses tumor cells” NCT07543848 ↗ |
| Modality | Other / unclassified | “oncolytic virotherapy” NCT05303844 ↗ |
| Route | Other | “will be first infused through the target artery” NCT01869088 ↗ |